Biomarkers · Cardiac & Hemodynamics

Galectin-3

Lower values go with lower risk of death. No risk curve catalogued yet.

Published risk of death1.10×per 1 SD increase in galectin-3 (95% CI 1.05–1.14) · Random-effects meta-analysis of 18 studies (32,350 participants; heart failure patients and general population combined), mean age 57.3

What else moves this marker

They describe those study groups, not an individual, and an association is not a cause.

Diseases and conditions

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↑ Diabetic nephropathy · DN patients vs controls, serum galectin-3	SMD +1.1 (95% CI 0.63 to 1.57)	diabetic nephropathy vs control patients · 9 studies, 3137 patients	meta analysis · PMID 37291488

Genetic predisposition

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↕ ABO locus (rs644234) · variance in plasma galectin-3 explained by the ABO locus	+3.8%	proportion of plasma galectin-3 variance explained · 3776 discovery subjects (HapMap-imputed) plus 3516 follow-up	gwas · PMID 23056639

Sources

Imran TF, Shin HJ, Mathenge N, et al. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. American Journal of Cardiology. 2017;119(1):57-64.